Christian Hordo, MBA, is Executive Vice President and Chief Business Officer at Sana Biotechnology leading the business development, corporate strategy drug development program leadership, and commercial functions.

Christian was most recently a Vice President at Juno Therapeutics, where he was the Multiple Myeloma program lead, responsible for progressing multiple drug candidates, including Juno’s BCMA CAR-T, through preclinical and clinical studies. He was also Juno’s Head of Business Development, where he built a team and led negotiations on multiple successfully executed transactions, including the broad strategic collaboration with Celgene. Prior to Juno, Christian spent five years at Genentech in business development and program leadership, successfully negotiating numerous transactions and leading a cross-functional drug development team for GDC-0134, a first-in-class small molecule for the treatment of ALS.

Christian earned his MBA from Harvard Business School, graduating with high distinction as a Baker Scholar, his MSc in medical genetics and microbiology from the University of Toronto and his BSc in psychology at McGill University.